Business Context and Reporting Period
This Form 8-K Current Report was filed by Integer Holdings Corporation on October 10, 2016. The filing primarily addresses Item 5.02 regarding the appointment of a new senior executive officer and the associated compensatory arrangements.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to the specific compensation package for the newly appointed Executive Vice President and Chief Operating Officer:
- Annual Base Salary: $550,000
- Short-Term Cash Incentive: Target of 80% of salary; Maximum of 155% of salary
- Long-Term Equity Award: Restricted stock units valued at $2,100,000 (vesting over three years)
- Stock Option Grant: 50,000 shares
- Relocation Expenses: Up to $10,000 for moving expenses plus reasonable temporary housing and airfare
Material Changes
The material change reported is the appointment of Jeremy Friedman, age 63, as Executive Vice President and Chief Operating Officer, effective October 10, 2016. Mr. Friedman previously served as President of the Company's Cardio and Vascular product group. This appointment includes a new employment agreement with specific severance and change-of-control provisions.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, outlook, or general risk factors. However, it details specific contingencies regarding Mr. Friedman's employment termination:
- Termination without Cause: Entitles the executive to 18 months of base salary and health/benefit continuation.
- Change of Control: If terminated within six months prior to or following a change of control (or voluntary termination for good reason), the executive is entitled to a lump sum equal to two times base salary and two times the greater of the average cash bonus or current target bonus, two years of benefit coverage, and accelerated vesting of equity awards (excluding performance-based awards).
Investor Verification Checklist
- Verify the impact of the new executive leadership on the Cardio and Vascular product group strategy.
- Review the total cost of the compensation package ($2.65M+ in initial value) relative to the company's current cash position.
- Assess the potential liability exposure under the change-of-control provisions if a merger or acquisition occurs.
- Confirm the vesting schedule details for the $2.1 million restricted stock unit award.